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Abstract
Detection of unknown single nucleotide polymorphism (SNP) relies on large scale sequencing
expeditions of genomic fragments or complex high-throughput chip technology. We describe a
simplified strategy for fluorimetric detection of known and unknown SNP by proportional
hybridization to oligonucleotide arrays based on optimization of the established principle of signal
loss or gain that requires a drastically reduced number of matched or mismatched probes. The
array consists of two sets of 18-mer oligonucleotide probes. One set includes overlapping oligos
with 4-nucleotide tiling representing an arbitrarily selected "consensus" sequence (consensus-
oligos), the other includes oligos specific for known SNP within the same genomic region (variant-
oligos). Fluorescence-labeled DNA amplified from a homozygous source identical to the consensus
represents the reference target and is co-hybridized with a differentially-labeled test sample. Lack
of hybridization of the test sample to consensus- with simultaneous hybridization to variant-oligos
designates a known allele. Lack of hybridization to consensus- and variant-oligos indicates a new
allele. Detection of unknown variants in heterozygous samples depends upon fluorimetric analysis
of signal intensity based on the principle that homozygous samples generate twice the amount of
signal. This method can identify unknown SNP in heterozygous conditions with a sensitivity of 82%
and specificity of 90%. This strategy should dramatically increase the efficiency of SNP detection
throughout the human genome and will decrease the cost and complexity of applying genomic wide
analysis in the context of clinical trials.
Background
The human genome project provides the first reference
sequence of all human chromosomes with the remaining
challenge of characterizing the frequency of deviations
from this reference among individuals [1]. It is estimated
that 1.42 million SNP are distributed throughout the
human genome and about 60,000 SNP fall within exons
[2]. Detection of SNP due to genetic variation in a given
population (polymorphisms) or epigenetic changes
throughout life (mutations) is important since it often has
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functional implications. In fact, 25 % of the known non-
synonymous SNP could affect the function of the corre-
spondent gene product [3–6]. Yet, it is still unclear
whether the prevalence of common diseases can be truly
attributed, at least in part, to SNP because of the incom-
plete information available about SNP prevalence
throughout the genome. The completion of the human
genome project could not provide comprehensive knowl-
edge about sequence variations because sequences are
based on information derived from randomly chosen
individuals [1,2] and there are only few examples of sys-
tematic searches for genetic variants within a specific
genomic region [7]. However, in the context of clinical
research a large number of individuals may need to be
screened when investigating associations between genetic
variation and disease susceptibility. In such an endeavor,
a tool capable of efficiently identifying known and flag-
ging unknown SNP could dramatically increase the effi-
ciency of the study of human pathology through direct
application of genome-derived information [8].
Known SNP can be readily detected using oligo-array-
based techniques [9–12] or comparable high-throughput
systems [13]-[14,15]. Detection of unknown SNP, how-
ever, is not as readily achievable because most current
methodologies are based on the utilization of probes
encompassing only known variant sequences [16,17].
Thus, identification of unknown SNP has relied on high-
throughput sequencing which is burdened by high cost
and demanding requirements for sample preparation. To
improve the efficiency of SNP detection, high-density oli-
gonucleotide arrays have been proposed that cover all
possible sequence permutations of the genomic region of
interest [7,9,18,19]. These arrays are characterized by
extreme accuracy not only for detecting but also in provid-
ing definitive sequence information about SNP [9]. How-
ever, for each genomic region a complex SNP array needs
to be assembled as for the 4L (length of nucleotide) oli-
gomer probes [9]. These arrays are composed of oligomer
probes that query sequential positions in the genome
spanning the length of the probe each one overlapping
the previous one of one base. For each position a set of
four oligos is prepared identical except at a single, gener-
ally central, position systematically substituted with each
of the four nucleotides. Thus for a given genomic region a
number of oligos equal to the number of bp investigated
times 4 is spotted to the array. To query a 16,569-base
pairs (bp) sequence 66,276 probes were necessary [9].
Similarly others have investigated BRCA1 and ATM genes
using 96,600 and >90,000 oligonucleotides for genomic
regions encompassing 3,450 and 9,170 bp respectively
[10,19]. Although this approach could potentially cover
the full genome, it might not be justified for genomic
areas with no polymorphism [9]. In addition, preparation
of these arrays would be disproportionate for genomic
areas with very low density of SNP. In those cases it would
be preferable to obtain more information about the loca-
tion of highly polymorphic sites prior to the design of 4L
tiled arrays or other comprehensive high-throughput sys-
tems. Finally, this approach would not be justifiable in sit-
uation where SNP occur extremely rarely in a given
population. In those cases a tool that could identify the
rare individuals carrying SNP could indicate few instances
where routine sequencing of a limited genomic region
could be more appropriate than the preparation of com-
plex high-density arrays. Thus, a simplified screening tool
that could discriminate conserved from polymorphic
genomic regions or identify rare individuals carrying unu-
sual SNP could dramatically restrict the use of high-
throughput sequencing or guide the production of high-
density 4L tiled arrays.
Results
We describe here a strategy that utilizes the well-estab-
lished principle of loss or gain of hybridization signal
[9,19]. for the screening of genomic regions that requires
~250 overlapping oligos to cover a 1 kb consensus
sequence (consensus oligos) or 4,142 rather than 66,276
oligos to cover a 16.569 bp genomic region as for the pre-
vious example [9]. Thus, the proposed strategy should be
considered a screening tool applicable for the investiga-
tion of unexplored areas of the human genome prior to
extensive sequencing expeditions or the construction of
high-density arrays. In addition, in situations where allelic
variation is already revealed, the array can be comple-
mented by a number of oligos equal to the number of
known SNP within that region. This number, therefore, is
proportional to the degree of pre-documented polymor-
phism of a given genomic fragment. This strategy pro-
poses a fluorimetric detection of SNP by proportional
hybridization to oligonucleotide arrays. The reference
sample, from a homozygous cell line identical to the con-
sensus (a,a), and test sample are amplified by PCR fol-
lowed by in vitro transcription to generate single stranded
RNA. Array data generated from hybridization of fluores-
cence-labeled reference (i.e. Cy3, green) and test (i.e. Cy5,
red) cDNA sample to consensus and additional oligos,
representing known SNP (variant oligos), is compared
and represented as natural log of the fluorescence inten-
sity ratio (LogRatio). In diploid organisms, four type of
combinations can occur: I) Homozygosity identical to the
consensus (a,a); II) Homozygosity different from the con-
sensus (b,b); III) heterozygosity containing one allele
identical and one different from the consensus (a,b); IV)
heterozygosity with both alleles different from the con-
sensus (b,c). Although this conceptually applies to whole
genes, in loci containing more than one polymorphic site,
this distinction applies to regions investigated by individ-
ual oligos; while, for the whole gene various combina-
tions can simultaneously occur. Thus, in this paper we willJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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refer to the various combinations by specifying ad hoc
whether we are referring to the whole gene or a specific
region of the same gene.
To illustrate this strategy, we selected a region of the
human genome spanning exon 2 of the Human Leukocyte
Antigen (HLA)-A locus, which contains multiple poly-
morphic sites (Figure 1). This gave us the opportunity to
identify different homo- heterozygous combinations
using genomic DNA from previously classified HLA-typed
Epstein-Barr virus-transformed B lymphoblastoid (EBV)
cell lines obtained from the European Collection of Ani-
mal Cell Cultures. The HLA type of all cell lines was veri-
fied using sequence-based typing methods [20].
According to conventional display, the HLA-A*0101
sequence was chosen as the consensus http://www.antho
nynolan.com/HIG/data.html. A set of 75 18-mer oligos
with 4-nucleotide tiling were selected to cover the HLA-
A*0101 allele from position 71 to 343. In addition, sev-
eral variant oligos relevant to the HLA phenotype of the
EBV lines tested were designed (Figure 2) with the SNP in
the centermost position to enhance the power of discrim-
ination caused by single nucleotide mismatch. Other
known SNP close to the 3' region were not covered by var-
iant oligos to test the capability to detect unknown vari-
ants ("unknown SNP" displayed in black in Figure 1).
HLA-A Locus, Exon II nucleotide sequence alignment of alleles relevant to the discussion of this manuscript Figure 1
HLA-A Locus, Exon II nucleotide sequence alignment of alleles relevant to the discussion of this manuscript. The consensus 
sequence is shown in green in areas containing polymorphic sites and in yellow at conserved areas (k oligos). Genomic regions 
covered by variant oligos are indicated by boxes with colored borders (red: HLA-A*02; violet: sub-types of HLA-A*02 differ-
ent from A*0201; green: HLA-A*0301, purple: HLA-A*2301; blue: HLA-A*29) corresponding to the sequences shown in Fig-
ure 2. Dashed borders indicate overlapping oligos. Dotted borders indicate variant oligos 1-SP-A-02a and b that contain an 
additional G > A switch in a peripheral region to test the influence of this mismatch in various conditions. In black are SNP in 
areas for which no variant alleles were designed ("unknown SNP"). The dashed line represents the areas where most 
"unknown SNP" are present for HLA-A*02 and A*29 (blue) or only for HLA-A*02 (orange).
80        90       100       110       120 130       140       150       160
*         *         *         *         *  *         *         *         *
A*0101     GCGGGCTCCCACTCCATGAGGTATTTCTTCACATCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCGCCGTGGGCTACGTGGACG
A*0201     --------T-----------------------------------------------------------------A----------------
A*0205     --------T-------------------A---C-----------------------------------------A----------------
A*0206     --------T-------------------A---C-----------------------------------------A----------------
A*0210     --------T-------------------A---C-----------------------------------------A----------------
A*0301     -------------------------------------------------------------------------------------------
A*2301     --A-------------------------C--------------------------------------------------------------
A*2901     ---------------------------AC--------------------------------------------------------------
170       180       190       200       210       220     230       240       250
*         *         *         *         *         *      *         *         * 
A*0101     ACACGCAGTTCGTGCGGTTCGACAGCGACGCCGCGAGCCAGAAGATGGAGCCGCGGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATT
A*0201     ------------------------------------------G------------------------------------T----------
A*0205     ---------------------------------------G--G------------------------------------T----------
A*0206     ------------------------------------------G------------------------------------T----------
A*0210     ------------------------------------------G------------------------------------T----------
A*0301     ------------------------------------------G-----------------------------------------------
A*2301     ------------------------------------------G-----------------------------------------------
A*2901     -------------------T----------------------G---------------A-------------------------------
260       270       280       290       300       310     320       330       340     
*         *         *         *         * *         *         *         *     
A*0101     GGGACCAGGAGACACGGAATATGAAGGCCCACTCACAGACTGACCGAGCGAACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGACG
A*0201     -----GG------------AG--------------------C------T-G---------------------------------------C—-
A*0205     -----GG------------AG--------------------C------T-G---------------------------------------C—-
A*0206     -----GG------------AG--------------------C------T-G---------------------------------------C—
A*0210     -----GG------------AG--------------------C------T-G---------------------------------------C--
A*0301     --------------------G----------G----------------T-G---------------------------------------C--
A*2301     -----G--------G----AG---------------------------A-------C---T-GC--T-C---------------------C--
A*2901     ------T-C-----------G----------G----------------------------------------------------------C--
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In case of a,a homozygosity, similar fluorescence intensity
is expected in both channels with a theoretical Cy5/Cy3
fluorescence intensity ratio = 1 (LogRatio = 0). This can be
experimentally tested by arbitrarily selecting genomic
fragments within the investigated region that, based on
available information, are most likely conserved in every
potential test sample (displayed in yellow in Figure 1) [2].
In this region, reference and test samples can be predicted
to be a,a homozygous. Consistent deflection from 0 of
LogRatios in these oligos denotes biases of labeled target or
reference. Thus, the average of the LogRatio for these oligos
is used as a normalization factor, constant (k), to correct
the bias of both channels in the rest of the data set. The
unlikely occurrence of SNP within the constant region
could still be detected since in such cases, the LogRatio of
one oligo will diverge from the rest of the constant region
oligos.
After normalization, individual oligos are investigated.
Homozygosity (a,a) is characterized by LogRatio ~0, digit-
ally displayed as yellow in the array image (Figure 3, row
I). Conversely, in the context of homozygosity different
from the consensus (b,b), specific hybridization of the test
sample to the variant oligo results in strong red (Cy5) sig-
nal (Va1 in Figure 3, row II) while the consensus oligo
spanning the same region reveals strong green signal
caused by hybridization of the reference sample only (Fig-
ure 3, row II). Non-specific low affinity hybridization to
an irrelevant variant oligo spanning the same regions is
similar for both reference and test sample resulting in flu-
orescence intensity ratios close to 1 (LogRatio ~0) (Va2 in
Figure 3, row II).
Since human genomes are diploid, polymorphisms can
occur in combinations and, therefore, detection of SNP
Variant oligos used in this study Figure 2
Variant oligos used in this study. Oligos are color coded to correspond to the regions described in Figure 1. *1-SP-A-02a and 
1-SP-A-02b contain one HLA-A*0201-specific mismatch and one additional mismatch (G > A in position 72).
Name of oligo Position 5' Sequence SNV SNV 3' sequence
1-SP-A-02 a* 70-87 70-CC G->A GGCTC C->T CACTCCATG-87
2-SP-A-02 b* 71-88 71-C G->A GGCTC C->T CACTCCATGA-88
3-SP-A-2901  90-106 90-GTATTTC TT->AC CACATCCG-106
4-SP-A-0205,0206 93-111 93-TTTCT T->A CAC A->C TCCGTGTC-111 
5-SP-A-02,30  136-153 136-TTCATCGC C->A GTGGGCTAC -153
6-SP-A-2901 b  172-189 172-GTGCGGTT C->T GACAGCGAC-189
7-SP-A-2901 a 173-190 173-TGCGGTT C->T GACAGCGACG-190
8-SP-A-0205  191-208 191-CcGCGAGCC A->G GA A->G ATGG-208
9-SP-A-02,A03,A23, A29 191-206 191-CCGCGAGCCAGA A->G GATGG-208
10-SP-A-29  211-229 211-CCGCGGGC G->A CCGTGGATA-229
11-SP-A-02 b  232-249 232-CAGGAGGG G->T CCGGAGTAT-249
12-SP-A-23 a  248-265 248-ATTGGGAC C->G AGGAGACAG-265
13-SP-A-02  248-265 248-ATTGGGAC CA->GG GGAGACAC-265
14-SP-A-03, A29  263-280 263-CACGGAAT C->G TGAAGGCCC-280
15-SP-A-23 b  291-308 291-TGACCGAG C->A GAACCTGCG-308Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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should be possible in the context of heterozygosity. This
discrimination can be achieved through fluorimetric
assessment of the hybridization pattern based on the gen-
eral principle that homozygous samples (two identical
alleles) will generate twice the amount of signal for a
given sequence than a heterozygous sample (Figure 3,
rows III-VII). In the context of heterozygosity, a single
allele hybridization to variant oligos generates a weaker
signal than in the homozygous condition resulting in a
lower LogRatio (specific hybridization over background).
(Figure 3, row III-V Va1 and row IV Va2). Competitive
hybridization to consensus oligos will lead to two pat-
terns. In a,b heterozygosity (portrayed as lighter green by
the digital image) at least one allele of the test sample will
hybridize to the consensus resulting in LogRatio depres-
sion of lesser magnitude (lighter green) than in b,b
Principle of fluorimetric detection of SNP by proportional hybridization to oligonucleotide arrays in homozygous and hetero- zygous conditions Figure 3
Principle of fluorimetric detection of SNP by proportional hybridization to oligonucleotide arrays in homozygous and hetero-
zygous conditions. Portrait of proportional hybridization (of differentially labeled reference (Cy3) and test (Cy5) sample to 
overlapping oligos encompassing an arbitrarily chosen "consensus" sequence (consensus oligos = CO) or variant-specific oligos 
(Va1 and Va2...., see Figures 1 and 2). The homozygous reference sample consists of two alleles identical to the consensus 
sequence (HLA-A*0101). Differentially fluorescence-labeled reference and test samples are co-hybridized to an array slide 
spotted with the 18-nucleotide overlapping consensus oligos and variant oligos. Four consensus oligos representing a "con-
served" region (k) were used to normalize the data set (see text). Reference sample consistently hybridizes to CO and never 
to Va oligos. Hybridization of test sample will determine variability in ratio of fluorescence intensity as portrayed by the digital 
images from a GenePix scanner. Possible combinations are: I) a,a type homozygosity (row I); II) b,b homozygosity (row II); III) 
a,b heterozygosity with one known allele (row III) and one unknown allele (row VII); IV) b,c heterozygosity with two known 
alleles (row IV), one known and one unknown allele (row V) and two new alleles (row VI). Question marks represent the 
hypothetical discovery of new allele(s).
Reference consensus DNA
from homozygous source
two identical alleles
CO1 and CO2
Test DNA
two alleles: 
Test1 and Test2
Fluorescence  intensity = +
Va2….……..
I)
II)
III)
IV)
V)
VI)
VII)
Va1
- -
-
- -
- -
co k
-
-
a,a homozygosity
b,b homozygosity
a,b heterozygosity
a,? heterozygosity
b,c heterozygosity
b,? heterozygosity
?,? homozygosity
or   heterozygosityJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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homozygosity where none of the test samples hybridizes
to the consensus (Figure 3, row III and VII). In b,c hetero-
zygosity none of the alleles hybridizes to consensus oligos
and, therefore, a situation similar to b,b homozygosity
occurs in the consensus oligos with strongly depressed
LogRatios (Figure 3, row IV-VI).
Hybridization conditions were optimized at variable
incubation times (Figure 4a) and temperatures (Figure
4b). Temperatures of 47°C for at least 4 hours yielded the
best hybridization results that were adopted thereafter.
Target density had no major repercussion on fluorescence
intensity ratio beyond 80 ng (data not show). Labeling
bias was assessed in conditions of a,a homozygosity by
co-hybridizing samples from an HLA-A*0101 source dif-
Effect of hybridization time (a) and temperature (b) in conditions of b,b type homozygosity (HLA-A*2091 labeled with Cy5 vs  HLA-A*0101 labeled with Cy3) Figure 4
Effect of hybridization time (a) and temperature (b) in conditions of b,b type homozygosity (HLA-A*2091 labeled with Cy5 vs 
HLA-A*0101 labeled with Cy3). b) LogRatio for Va (HLA-A*2901-specific) oligos (red), k-oligos (yellow) and CO-oligos. c) Test 
for labeling bias and reproducibility in conditions of a,a homozygosity and b,c heterozygosity: gene pix image. d) Scatter plot of 
Cy3 and Cy5 fluorescence intensity in conditions of a,a homozygosity. In red are portrayed Va oligos; in green k and consensus 
oligos. A cluster of consensus oligos with poor hybridization kinetics due to high CG content (average of 75%) is portrayed in 
light blue. Reproducibility was tested in conditions of b,b homozygosity (HLA-A*0201 vs HLA-A*0101) and a,b heterozygosity 
(HLA-A*0101, 2901 vs HLA-A*0101) by reciprocally labeling test and reference targets in duplicate experiments as shown by 
the clusterogram. In spite of variable hybridization kinetics, differential hybridization could be observed consistently among Va 
and corresponding consensus oligos. Only HLA-A*0201-specific and relevant homologous consensus oligos (solid red and 
green bar respectively) or HLA-A*2901-specific oligos (dashed red line) are shown.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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ferentially labeled with Cy5 and Cy3 (Figure 4c). Good
correlation of Cy5 with Cy3 signal intensity was observed
based on individual oligo although the kinetics of hybrid-
ization varied remarkably among different oligos Figure
4d. In general, the hybridization efficiency correlated to
the theoretical expectation that the variant oligos (red in
the scatter plot) should have low affinity for HLA-A*0101
targets. However, exceptional variant oligos with strong
hybridization affinity to HLA-A*0101 and, conversely, a
cluster of consensus oligos (average CG content = 75%,
range 67 to 94%) with poor hybridization kinetics (blue
in the scatter plot) were noted. Strong hybridization of the
reference sample to a variant oligo could be associated
with GC rich oligo or a T → A or T → C replacement, while
decreased hybridization of reference sample to consensus
oligo could be caused by self-annealing of GC rich
sequences. These, fluctuations in strength of
hybridization had, however, little impact on the analysis,
since differential hybridization could still be easily
detected when samples from different genotypes were
tested (clusterogram in Figure 4d). For instance, reciprocal
labeling in the context of b,b homozygosity or b,c hetero-
zygosity demonstrated perfect symmetry in hybridization
to variant and consensus oligos.
Data could be ordered sequentially into genotypic profiles
according to sequence position. The a,a  homozygosity
phenotype was characterized by LogRatios with minimal
deviation from 0 (Figure 5a,5F). Conversely, b,b homozy-
gosity yielded extremely high LogRatios in variant oligos
and strongly depressed LogRatio in the corresponding con-
sensus oligos (Figure 5b). Noteworthy is the pattern of
proportional hybridization to the variant oligo p  (p  =
oligo 13-SP-A-02 at position 248–265) that encompasses
a double nucleotide variant from CA → GG in position
256–257. The oligo containing this double mismatch fur-
ther reduced the hybridization affinity to the reference
sample, proportionally enhancing the affinity of the test
sample leading to higher LogRatio for oligo p in Figure 5b.
The "unknown" SNP (from position 250 to 310) was
revealed by absence of variant-specific hybridization but
highly depressed LogRatios of the corresponding consen-
sus region oligos (orange asterisks and dashed line in Fig-
ure 5b). This phenomenon may exemplify the ability of
this method to detect allelic variants in the absence of var-
iant-specific oligos. Even in conditions of a,b heterozygos-
ity (Figure 5c), "unknown" SNP could be suspected due to
the relatively reduced LogRatios (0.5 ~1) in variant oligos
and more characteristically less depressed LogRatios in cor-
responding consensus oligos compared with b,b homozy-
gosity (Figure 5b). Noteworthy is the exceptional
behavior of the variant oligo p  that contains a double
nucleotide variant (p in Figure 5c) which leads to higher
LogRatios even in the context of a,b heterozygosity. How-
ever, the corresponding consensus oligos are not affected
by the double nucleotide variant and, therefore, display a
typical  a,b  heterozygosity pattern distinguishable from
b,b homozygosity since one allele in the test sample is
identical to the reference.
Heterozygosity with both alleles different from the con-
sensus (b,c) represents the most complex situation (Figure
5d). In this case, heterozygous samples such as A*0201,
2901, LogRatios behave as in b,b homozygosity at this spe-
cific region since both alleles hybridize to the same variant
oligo and neither to the correspondent consensus oligos.
The discriminatory power of this phenomenon can be
better illustrated by comparing the hybridization pattern
of the same oligo in conditions of b,b  homozygosity
(HLA-A*2901 homozygous) and a,b  heterozygosity
(HLA-A*0101,2901 heterozygous) (x in Figure 6). In this
case, differential hybridization pattern is marked by dou-
bling and halving of LogRatios in variant and consensus
oligos respectively (see also Table in Figure 6). Thus, vari-
able types of heterozygosity in the test sample may affect
differently the proportional hybridization to the corre-
spondent consensus oligos. An extreme example occurs
when one allele of the test sample hybridizes to the vari-
ant oligo (14-SP-A*29; position 263–280) while an
unknown SNP is present in the other allele within the
same region (HLA-A*0201, y in Figure 5d). This exempli-
fies a case of b,c  heterozygosity in which one SNP is
unknown as theorized in row V, Figure 3. In this case, a
reduced  LogRatio in the variant oligo associated with
extremely depressed LogRatios in the corresponding con-
sensus oligo are observed because both test alleles are dif-
ferent from the consensus. The power of discrimination
a,b and b,c heterozygosity in regions with "unknown "
SNP is underlined by the dashed line in Figure 5d. The
blue line highlights polymorphisms occurring in both
alleles (A*0201,2901). Thus, the corresponding consen-
sus oligos display strongly depressed LogRatios compara-
ble to b,b type homozygosity. In the following region, the
dashed orange line indicates polymorphisms occurring
only in one allele (A*0201 and not 2901) resulting in less
depressed LogRatios in the corresponding consensus oligos
as in the case of a/b heterozygosity.
Occurrence of more than one SNP within an oligo could
complicate the data analysis. For instance, in the case
described in Figure 5d, two regions with a double mis-
match are observed which are characterized by LogRatios
disproportionately high for the HLA-A*0201/2901
heterozygous state (p and q depict oligos 13-SP-A-02 and
3-SP-A-2901 respectively, specific for the two alleles). In
conditions of HLA-A*0201/2901 heterozygosity, consen-
sus oligos corresponding to polymorphism p representing
A*0201, strongly hybridized to the reference sample
resulting in a b,b homozygosity hybridization pattern. InJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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the case of polymorphism q representing A*2901 variant,
the same A*0201 region is identical to the consensus and,
therefore, a,b heterozygosity pattern is observed.
An unexplainable finding was observed where specific
hybridization to a variant oligo is not associated with
depressed LogRatios of the correspondent consensus oligo
(z in Figure 5d). A purposeful mismatch, a C → A switch,
may have less repercussions on the hybridization pattern
of this oligo. Indeed, even in homozygous conditions (z
in Figure 6) the LogRatios are only minimally depressed in
this case. In these relatively rare occurrences (only case in
our study) an "unknown" polymorphism would not be
detected.
Profiling by proportional hybridization of HLA-A exon 2 Figure 5
Profiling by proportional hybridization of HLA-A exon 2. Four patterns are described: a,a homozygosity (A); b,b homozygosity 
(B); a,b heterozygosity (C) and b,c heterozygosity (D). Each bar represents the LogRatio for individual oligos sequentially posi-
tioned in 3' to 5' direction. Variant oligos are nested between homologous consensus oligos and appear as bright (LogRatio >1) 
or light red (LogRatio > 0.5 and ≤ 1). LogRatio for any oligo between ≤ 0.5 or ≥ -0.5 are shown in yellow. Consensus oligos in 
various conditions of mismatch with test DNA are shown as light (LogRatio < -0.5 and ≤ -1) or dark (LogRatio < -1) green. The 
orange lines delimit LogRatio between 1 and -1. The letter p points to a variant oligo with a double nucleotide variant (CA → 
GG at 256–257). Another double mismatch-containing oligo is pointed out by q (CA → AC at 99–100). The letter x points to 
a variant oligo (9-SP-A-02) spanning a region of b,c type heterozygosity (HLA-A*0201 and A*2901 differ A → G from the con-
sensus). The letter y points to a situation where a variant oligo (14-SP-A-03, A29 at 263–280) encompasses also a "unknown" 
SNP present in the other allele (HLA-A*0201). z shows a variant oligo (10-SP-A-29 at 211–229) whose increased LogRatio is 
not associated with decreased LogRatio in the homologous consensus oligo. The orange asterisks and the dashed lines show a 
genomic region in which "unknown" HLA-A*0201 polymorphisms are associated (blue) or not associated (orange) with HLA-
A*2901 polymorphic sites.
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To statistically assessed the ability of this method to dis-
criminate differences between a,a  homozygosity from
other combinations in conditions of unknown SNP, we
analyzed the behavior of consensus oligos only in various
experimental conditions. For each 18-mer probe, starting
from 3rd base and ending at 16th base, if the test target
contained at least one single nucleotide different for the
consensus sequence HLA-A*0101, we considered this spe-
cific region SNP(+); otherwise it was SNP(-). Various com-
binations were tested as shown in Figure 7. In all
permutations tested (given appropriate sample size) the
set of 4-nucleotide tiling consensus oligo alone demon-
strated a high SNP discriminatory power. In particular,
even the theoretically most problematic combination (a,b
vs a,a), least divergent from the consensus, could be easily
significantly discriminated in all permutations tested.
We then tested the sensitivity and specificity of this strat-
egy by examining the relationship between LogRatio and
the actual SNP condition via ROC (Relative Operating
Characteristics) analysis [21]. The ROC curves in Fig. 5
were composed of 3 different groupings. As it could be
expected, optimal threshold for detection of polymor-
phism related sensitivity and specificity varied according
to the allelic combination. When the test sample is most
different from the consensus reference as for b,b an b,c
Genomic "fingerprinting" using proportional hybridization Figure 6
Genomic "fingerprinting" using proportional hybridization. Description of individual genotype combinations. Four allelic combi-
nations are described here using graphics similar to the ones described in Figure 5. The data for each allelic combination repre-
sent the average LogRatio ± SDev of three separate tests. In the accompanying Table, the LogRatio in variant oligos and 
corresponding homologous consensus oligo are shown for b,b homozygosity (HLA-A*2901 vs reference HLA-A*0101) and a,b 
heterozygosity (HLA-A*0101, A*0201 vs reference HLA-A*0101) that are portrayed by the top two bar graphs.Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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higher accuracy with sensitivity 82% and specificity 96%
is observed (red line). The worst accuracy was noted when
test and reference samples were closest as in the case of a,b
heterozygosity (sensitivity 82% and specificity of 82%)
(blue line). The most informative analysis was, however,
provided using data from all the possible combinations
(green line in Figure 8) since in most common experimen-
tal condition the relationship between test and consensus
sample is not known and, therefore, all possible allelic
combinations should be expected. In that case an optimal
threshold of LogRatio ≤ -0.62 yielded sensitivity at 82%
and specificity at 89%. Thus, this strategy may identify 4
out of 5 SNP with 90% accuracy with the highest chance
of discriminating false positive result when an a,b hetero-
zygous sample is tested.
Discussion
In this study, we describe a simplified strategy for the
detection of known and unknown SNP that, because of
the decreased cost, could be applied to large clinical
studies. A flow chart describing the algorithm for the iden-
tification of SNP using this method is shown in Figure 9.
Although this strategy was conceived to identify SNP in
genes for which little is known about their polymor-
phism(s), it could also be used for routine typing of
known alleles. This could be achieved by preparing allele-
specific profiles and matching test results with known per-
mutations collected in databases compiling repeated
hybridization profiles as template to eliminate possible
false interpretations. Annotation of the test sample geno-
type will be reported after comparison with established
templates. The HLA alleles and corresponding oligos used
Degree of discrimination among different HLA alleles using proportional hybridization to oligonucleotide arrays Figure 7
Degree of discrimination among different HLA alleles using proportional hybridization to oligonucleotide arrays. Two sample t-
tests were used to differences between two means. P-values were calculated for each (a,b) vs.(a,a); (a,b) vs. (b,b); and (b,b) vs. 
(a,a)
t-test comparison of Log2Ratio differences among various allele combinations
Allelic Combination #samples Allelic 
Combination
#samples df p-value
(b,b)( a,a)
A0201 2 A0101, A0101 4 4 0.00001
A0301 1 A0101, A0101 4 3 0.0008
A2301 1 A0101, A0101 4 3 0.0002
A2901 8 A0101, A0101 4 10 0.0003
(a,b) (a,a)
A0101,0201 1 A0101,A0101 4 3 0.0015
A0101,0301 1 A0101,A0101 4 3 0.0025
A0101,2301 2 A0101,A0101 4 4 0.0015
A0101,2901 5 A0101,A0101 4 7 0.0008
(b,b)( a,b)
A0201 2 A0101,0201 1 1 0.0819
A2301 1 A0101,2301 2 1 0.0554
A2901 8 A0101,2901 5 11 0.0003Journal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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here were selected to exemplify various combinations.
Various permutations of homozygosity and heterozygos-
ity can be observed that produce complex hybridization
patterns highly specific for a particular phenotype. In
these highly polymorphic conditions, each haplotype
combination maintains a highly reproducible profile
characterized by minimal variance. This allows the crea-
tion of "genotypic masks" within narrow ranges of varia-
tion to "fingerprint" known haplotype permutations for
high-throughput typing of highly polymorphic genes.
We, therefore, describe a potentially powerful and effi-
cient strategy for high-throughput screening of genes for
which little is known about their polymorphism. This
Sensitivity and specificity analysis of the strategy Figure 8
Sensitivity and specificity analysis of the strategy. 18-mer probes were assigned to SNP (+) if the sequence of the test channel 
probe of a specific spot contained at least one single nucleotide different from the sequence A*0101. The other probes were 
considered SNP(-). ROC (Relative Operating Characteristic) analysis [21] of curves for 3 different allelic combinations. The red 
line represents a ROC curve generated from 448 spots in 7 b,b homozygosity and b,c heterozygosity experiments with 269 
SNP(-) and 179 SNP(+) spots. The blue line represents ROC curves generated from 265 spots in a,b heterozygosity experi-
ments with 169 SNP(-) and 87 SNP(+) spots. The green line represents a ROC curve from 704 spots in all experiments with a 
total of 438 SNP (-) and 266 SNP (+) spots. The dots on the curves stand for optimal threshold in each group. Threshold for 
LogRatio were based on ROC analysis to balance sensitivity and specificity. For the group with b,b and b,c heterozygosity (red 
line) experiments the optimal threshold was a LogRatio ≤ -0.91. The sensitivity using this threshold was 82% and specificity 96%. 
The optimal threshold for the a,b heterozygosity (blue line) was LogRatio ≤ -0.43 with a sensitivity of 82% but a specificity drop 
to 82%. For the analysis combined all the data (green line) the optimal threshold was LogRatio ≤ -0.62 with a sensitivity at 82% 
and specificity at 89%. This last ROC exemplifies the most common experimental condition where the relationship between 
test and reference sample is not known and, therefore, all possible allelic combinations should be expected.
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strategy could also be used to identify mutations in dis-
ease processes or for typing known allelic variants of well-
characterized genes such as HLA. This, however, would
require specialized design of numerous oligos encom-
passing known variants and supportive software for effi-
cient data interpretation. Various scenarios are best
exemplified by using as a model a highly polymorphic
region of the human genome such as exon 2 of the HLA-
A locus. The simplest case would be the investigation of a
gene characterized by minimal or no polymorphism. In
this case, screening of samples from different ethnic
groups would yield a pattern described as a,a  type
homozygosity, similar to the one shown in Figure 8a.
Another possibility would be the investigation of a gene
with few but relatively common polymorphism(s). In this
case the occurrence of b,b type homozygosity would be
common as depicted in Figure 8b. In the same situation,
a,b  type heterozygosity would also frequently occur as
shown in Figure 8c. Finally, a most complex scenario,
likely to occur only for genes characterized by high poly-
morphic prevalence is portrayed in Figure 8d. In this case,
b,c type heterozygosity should occur frequently as it might
be expected for the HLA loci. However, SNP occur in the
human genome on average every 600 – 2,000 bases [1,2].
Therefore, most genes are characterized by a relatively
narrow range of polymorphism that would allow a rela-
tively simple design of oligo-array chips and interpreta-
tion of results. Independently of the genomic region
investigated, this strategy can identify unknown variants
through observation of disproportionably depressed
LogRatios in consensus oligos.
Flow chart summarizing the proposed algorithm to screen for known or novel SNP using proportional hybridization to oligo- nucleotide arrays Figure 9
Flow chart summarizing the proposed algorithm to screen for known or novel SNP using proportional hybridization to oligo-
nucleotide arrays.
Test DNA Reference DNA*
Hybridization to consensus oligos
Balanced Unbalanced
No SNP Hybridization to known SNP oligos
Positive
Known SNP
Negative
New SNP
Identification by sequencing of polymorphic region
* Reference DNA is identical to consensusJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/4
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Conclusions
The SNP detection system described her may provide a
great improvement in the ability to screen different genes
for the frequency and location of polymorphic sites,
which ca be confirmed by site directed sequencing limited
to the region of interest. Thus, the best application of this
strategy stems from the clinical need to rapidly segregate
genes characterized by presence or lack of polymorphisms
in their coding or regulatory regions that may affect clini-
cal behaviors. A good example of such application is the
screening of cytokines, chemokines and their receptors
whose polymorphism(s) have been associated to individ-
ual predisposition to immune pathology, survival of
transplanted organs and predisposition to cancer [16,22–
25].
Material and methods
Oligo nucleotide probe design
The HLA-A locus exon 2 region from position 73–346,
allele A*01011, was used for the design of consensus
oligos (Figure 1). Allele-specific (variant) oligos were
designed based on single or double nucleotide variants
according to alignment to the arbitrarily selected consen-
sus sequence (HLA-A*0201). Variant and consensus
oligos consisted of 18-mers with a 5' amino-modifier hav-
ing a six-carbon spacer for immobilization (Operon Tech-
nologies, Inc, Alameda, CA). The polymorphic site in the
variant oligos was designed in the centermost position.
Melting temperatures of oligo probes were maintained as
close as possible to a range of 56–60°C. 350–400 pmol/µ
l oligo probes synthesized in 96-well format were dried
and re-suspended in 3 × SSC for printing.
Oligonucleotide array printing and post process of slides
Probes were spotted onto a 3D-link activated slide for cov-
alent immobilization (Motor roller) using OmniGrid
robotic printer (Genemachine) with four printing pins
picking up 0.25 µl of probe solution and depositing 0.6 nl
per spot (TeleChem International, Inc.). Each spot was
quadruplicated to minimize printing bias and test repro-
ducibility. Spot diameter was 90–100 µm, spaced at 250
µm to prepare 4 × 16 × 6 spot/arrays. After printing, slides
were kept in a sealed humidifier chamber at room temper-
ature overnight and blocked with 50 mM ethanolamine,
0.1 M Tris, pH9 and 0.1% SDS at 50°C for 15 minutes fol-
lowed with rinsing in water twice, washing with 4 × SSC/
0.1% SDS 50°C for 45 minutes, rinsing with water briefly
and centrifuging at 800 rpm for 3 minutes with micro-
plate carriers. Arrays were then stored in a desiccator until
use.
Test and consensus reference samples
Genomic DNA was isolated from EBV transformed B cell
line. 12 heterozygous or homozygous samples were tested
for oligo nucleotide array hybridization and confirmed by
sequence-based typing using the ABI Prism 3700-96
Analyzer.
Preparation of target nucleic acids
In order to generate single strand DNA, PCR products
from Exon 1 to Exon 5 of the HLA-A locus were amplified
with an attachment of T7 promoter to the 5' end using 5'
T7-EX1A-6 primer
5'AAACGACGGCCAGTGAATACGACTCACTATAGGCGC
CAGACGCCGAGGATGGCC3') and three 3' primers (3'
EX 5-A 993-1 CAT TGC TGG CCT GGT TCT CC; 3' EX 5-A
993-2 CAT TGC TGG CCT GGT TCT CTT; 3' EX 5-A 993-3
CAT TGC TGG CCT AGT TCT CTT). PCR reaction was
mixed with 25 µl of HotStart PCR reagents (Qiagen, CA),
5 ng-0.5 µg of genomic DNA, 5 µl of 15 µM 5'primer, 5 µl
of 15 µM 3'primer mix and H2O to a 50 µl final volume.
The reaction was cycled at 95°C for 10 minutes, 96°C for
35 seconds, 65°C for 45 seconds, 72°C for 3 minutes, 4
cycle; 96°C for 30 seconds, 60°C for 40 seconds, 72°C for
3 minutes, 19 cycles and 96°C for 30 seconds, 55°C for
40 seconds, 72°C for 2 minutes, 9 cycles. One µl of PCR
product from each sample was analyzed using a Bioana-
lyzer on DNA7500 chip (Agilent Biotechnology).
Approximately 2,000 bp amplicons from each sample
were amplified. The PCR products were then precipitated
with EtOH at room temperature and re-suspended in
DEPC-treated H2O at 0.1 µg/µl concentration. In vitro
transcription (IVT) was performed using an Ambion T7
Megascript Kit (Cat. #1334). For each sample, the follow-
ing reaction mixture was made: 4 µl of each 75 mM NTP
(A, G, C and UTP), 4 µl reaction buffer, 4 µl enzyme mix
(RNase inhibitor and T7 phage polymerase) and 1 µg
purified PCR product in 16 µl DEPC-treated H2O. The
reactions were then incubated at 37°C for six hours to per-
mit transcription. Amplified RNA was then purified using
TRIzol reagent according to manufacture instruction (Gib-
coBRL) and re-suspended in 40 µl of DEPC water. RNA
concentrations were estimated by using a Bioanalyzer on
RNA 6000 chip (Agilent Biotechnology).
Target labeling and hybridization
Fluorescence-labeled single strand cDNA was generated
by reverse transcription (RT) and used for hybridization.
In the RT reaction, 4 µl of first strand buffer, 1 µl random
hexmer (8 µg/µl; Boehringer Mannheim), 2 µl 10 × low T-
dNTP (5 mM A, C and GTP, 2 mM dTTP), 2 µl 1 mM Cy-
dUTP (Cy3 for reference sample or Cy5 for test sample
unless otherwise specified), 2 µl 0.1 M DTT, 1 µl Rnasin
and 1.2 µg amplified RNA in 8 µl DEPC H2O were mixed
and heated for five minutes at 65°C. This was followed by
addition of 1 µl Superscript II (Life technology,), 40 min-
utes of incubation at 42°C, another 1 ul of Superscript II
and 50 more minutes continued incubation at 42°C.
Reactions were stopped by addition of 2.5 µl 500 mM
EDTA, 5 µl 1 M NaOH and heated to 65°C for 15 minutePublish with BioMed Central    and   every 
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to hydrolyze the RNA. Tris buffer (12.5 µl of 1 M) was
added immediately to neutralize the pH, and the volume
risen to 70 µl by adding 35 µl of 1 × TE. Target solution
was then applied to Bio-6 column according to the man-
ufacturer's instructions. The flow through mixed with 200
µl 1 × TE was concentrated to 20–40 µl using Microcon
YM-30 column (Millipore) and further concentrated to 8
ul using speed-vacuum.
Cy3- and Cy5-labeled probes were combined (1:1 ratio)
and 5 µl 20 × SSC, 0.5 µl 10% SDS and 0.5 µl of 4 mg / ml
salmon sperm DNA were added to the probe for
hybridization. The samples were then heated for two min-
utes at 99°C. Prepared probe mixture was applied to an
array slide with cover slid and hybridized at 47°C for dif-
ferent amounts of time as described in the text. Slides were
washed with 4 × SSC, 2 × SSC with 0.1 % SDS, 1 × SSC,
0.2 × SSC and 0.05 × SSC sequentially for one minute each
step and dried by centrifugation at 800 rpm for 3 minutes.
The slides were then scanned for fluorescent signal using
a GenePix 4000B scanner and the results analyzed using
GenePix Pro3 software (Axon Instruments, Inc.).
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